Precision Medicine in Breast Cancer
Objectives
The main objective of the project «precision medicine in breast cancer: biomarker identification» run by the Translational Research & Precision Medicine Team at the Cyprus Cancer Research Institute is to improve our understanding of the mechanisms underlying the biology of breast cancer through the identification of novel biomarkers following the precision medicine paradigm.
The project will create new and strengthen existing collaborations amongst the members of the CCRI organisations, enhancing the significance of multidisciplinary approaches in cancer research. New scientific knowledge, skills and expertise will be generated allowing for the expansion of the research organisations’ portfolio. Current clinical service will be largely benefited by the knowledge and experience exchange between bench and bedside.
- Results
- MDK Poster
The preliminary results of the “Precision Medicine in Breast Cancer: Biomarker Identification” project were presented in the recent 1st Cyprus Oncology Congress held in Nicosia 6-8 February 2025.
In the context of this project, 100 breast cancer cases have been analyzed in relation to the expression of MDK. Promising results suggest that MDK can help identify early response or resistance to therapy in metastatic breast cancer.
The project aspires to analyze more cases with both early and metastatic breast cancer to fully define the prognostic and predictive role of this biomarker.
“Precision Medicine in Breast Cancer: Biomarker Identification” is the first Research and Innovation Foundation (RIF)-funded project in CCRI, initiated in July 2022 and led by Dr. Anastasia Constantinidou, the Group Leader of the Translational Research and Precision Medicine Institutional Team at CCRI.
Click here for the MDK Poster
